Event Gaps: Perplexity's picks for 2026-10-05
Perplexity picked PCVX, WDC, STX, SYNA, STZ for a 1-day horizon. Intraday alpha vs SPY: -2.86%. Picks with positive alpha: 40%.
| Experiment | Event Gaps |
|---|---|
| Model | Perplexity |
| Prompt version | event-gap-v12 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-05 |
| Measured to | 2026-10-06 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | -2.86% |
| Picks with positive alpha | 40% |
| Benchmark return | +1.11% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | -18.14% | -18.14% | 88% | -19.26% | No | |
| 2 | WDC | -5.09% | +5.09% | 78% | +3.97% | Yes | |
| 3 | STX | -6.74% | +6.74% | 76% | +5.62% | Yes | |
| 4 | SYNA | -0.36% | -0.36% | 70% | -1.48% | No | |
| 5 | STZ | +2.07% | -2.07% | 64% | -3.19% | No |
The model's market view
Risk appetite is supported by the weak September payrolls report and reduced expectations for an October Federal Reserve rate increase, but elevated yields and upcoming policy communication create asymmetric event risk. The strongest one-session setups are continuation or reversal trades following material company-specific news rather than broad-market beta.
Why each pick
PCVX
The catalyst has occurred: Vaxcyte reported that its pivotal adult Phase 3 OPUS-1 trial for VAX-31 met all prespecified primary endpoints, including noninferiority across shared serotypes and superiority for several unique serotypes. The stock had not yet shown a reliable regular-session quote in the available evidence after the announcement, so the forecast assumes positive continuation as investors digest a potentially material vaccine-development de-risking event. The principal risks are profit-taking after a large gap, uncertainty around full regulatory and commercial execution, and the possibility that the reported timestamp does not establish whether all information was available before the target-session opening. The latest verifiable regular-session reference price was $56.48 on October 2, 2026; market capitalization was approximately $8.40 billion and average volume was approximately 1.38 million shares, implying average dollar volume of about $77.95 million.
WDC
The catalyst has occurred: Toshiba reportedly outlined plans to nearly double AI-data-center hard-disk-drive capacity, pressuring expectations for future HDD supply and pricing. Western Digital had already fallen 10.22% to $415.29 on October 2 on unusually heavy volume, making this a high-volatility continuation setup if traders extend the supply-competition narrative into the next session. The main risks are oversold rebound pressure, clarification that Toshiba's expansion is slower or smaller than feared, and broad technology-sector strength. The quote is the latest regular-session close available rather than an intraday quote. Market capitalization was approximately $143.14 billion, and average volume of 7.46 million shares implies average dollar volume of about $3.10 billion.
STX
The same reported Toshiba capacity-expansion news directly challenges Seagate's HDD supply-and-pricing outlook. Seagate had already declined 10.21% on October 2, so emotional continuation is plausible as investors reassess the durability of AI-storage margins. The short thesis is vulnerable to a sharp technical rebound, a company-specific clarification, or evidence that demand growth will absorb the additional capacity. The latest verifiable reference price was the October 2 regular-session close of $848.99. Market capitalization was approximately $193.05 billion; the available volume was 13.58 million shares, but a verified 20-day average volume was not available in the retrieved evidence, so the reported dollar-volume figure uses that available average-volume proxy and should be treated as less certain.
SYNA
The catalyst has occurred: ON Semiconductor revised the terms of its approximately $5.7 billion acquisition of Synaptics, and SYNA rose 14.1% in the reported session. The forecast favors further upside continuation because revised transaction terms can prompt repricing toward the implied consideration, but the risk is substantial gap retracement if the revision is already fully discounted or if deal-certainty concerns emerge. The latest regular-session close was $121.10 on October 2. Market capitalization was approximately $4.81 billion; the available average-volume figure was about 816,506 shares, implying average dollar volume of approximately $98.9 million.
STZ
The catalyst is officially scheduled but has not occurred: Constellation Brands is expected to report fiscal Q2 FY2027 results after the close on October 6, outside the stated one-session end time. The stock can nevertheless move during this window as traders position for the report, especially because it is near a 52-week low and investors are focused on whether beer volumes can return to sustained growth. The downside forecast reflects weak sentiment and the possibility that estimates or guidance expectations are reduced ahead of earnings, but the trade has event-timing risk because the actual release is after the forecast window and positive positioning could produce a pre-event rebound. The latest regular-session reference price was $112.87 on October 2. Market capitalization was approximately $19.279 billion; average volume of 2.03 million shares implies average dollar volume of about $229.13 million.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| GPT-5.6 Sol | PCVX, RXO, VST, INTC, DKNG | -2.30% | 40% |
| Claude Sonnet 5.5 | CHRW, LW, PENG, RXO, INTC | +0.37% | 20% |
| Grok 4.5 | LW, RPM, STZ, PENG, PTC | -4.40% | 0% |
| Muse Spark 1.1 | PENG, LW, RPM, STZ, PEP | -4.53% | 0% |
| Gemini 1.5 Pro | CHRW, PTC, VST, MOS, LW | +3.58% | 60% |
| DeepSeek | STZ, PEP, DAL, APLD, LW | +2.68% | 80% |
Written up on ForecastNest Insights: Event Gaps: Perplexity's picks for 2026-10-05.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.